Literature DB >> 9027594

Relevance of cyclin D1 and other molecular markers to cancer chemoprevention.

I B Weinstein1.   

Abstract

Until recently studies on mutations in cellular genes implicated in multistage carcinogenesis have concentrated mainly on dominant acting mutations in cellular proto-oncogenes, genes that normally mediate agonist-induced signal transduction pathways, and recessive mutations in cellular tumor suppressor genes, whose normal products appear to inhibit cell growth and/or control differentiation and cell-cell interactions. It seems likely, however, that a third category of cellular genes, the cyclins and cyclin-related genes, may also be critical targets during multistage carcinogenesis because of the central role that they play in controlling cell cycle progression. These proteins could, therefore, provide biomarkers for identifying individuals at high risk of developing cancer and also serve as novel targets for chemopreventive agents. This paper reviews evidence that the gene cyclin D1 is amplified and/or overexpressed in a major fraction of human tumors, and that this can occur relatively early in the carcinogenic process. Mechanistic studies indicates that this overexpression plays a critical role in tumor progression as well as the maintenance of the tumorigenic phenotype. Thus, increased cyclin D1 expression can enhance gene amplification and cell transformation and antisense to cyclin D1 can revert malignant cells. The latter findings provide direct evidence that cyclin D and related proteins might be useful markers and also targets for cancer chemoprevention.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 9027594

Source DB:  PubMed          Journal:  J Cell Biochem Suppl        ISSN: 0733-1959


  12 in total

1.  The invasion front of human colorectal adenocarcinomas shows co-localization of nuclear beta-catenin, cyclin D1, and p16INK4A and is a region of low proliferation.

Authors:  A Jung; M Schrauder; U Oswald; C Knoll; P Sellberg; R Palmqvist; G Niedobitek; T Brabletz; T Kirchner
Journal:  Am J Pathol       Date:  2001-11       Impact factor: 4.307

2.  A better cell cycle target for gene therapy of colorectal cancer: cyclin G.

Authors:  Rodrigo Perez; Nancy Wu; Adam A Klipfel; Robert W Beart
Journal:  J Gastrointest Surg       Date:  2003-11       Impact factor: 3.452

Review 3.  Cyclin D1 and human neoplasia.

Authors:  R Donnellan; R Chetty
Journal:  Mol Pathol       Date:  1998-02

4.  Inhibition of tumor growth and metastasis by non-small cell lung cancer cells transfected with cyclin D1-targeted siRNA.

Authors:  Hu Huang; Yi-de Hu; Na Li; Yong Zhu
Journal:  Oligonucleotides       Date:  2009-06

5.  Tissue array for Tp53, C-myc, CCND1 gene over-expression in different tumors.

Authors:  Guo-Yan Liu; Qi Luo; Bin Xiong; Chao Pan; Ping Yin; Hong-Feng Liao; Wei-Chun Zhuang; Hong-Zhi Gao
Journal:  World J Gastroenterol       Date:  2008-12-21       Impact factor: 5.742

Review 6.  Discovery of cancer preventive agents from natural products: from plants to prevention.

Authors:  Rajendra G Mehta; John M Pezzuto
Journal:  Curr Oncol Rep       Date:  2002-11       Impact factor: 5.075

7.  Cisplatin-induced apoptosis in rat dorsal root ganglion neurons is associated with attempted entry into the cell cycle.

Authors:  J S Gill; A J Windebank
Journal:  J Clin Invest       Date:  1998-06-15       Impact factor: 14.808

8.  Mediation of estrogen mitogenic effect in human breast cancer MCF-7 cells by PC-cell-derived growth factor (PCDGF/granulin precursor).

Authors:  R Lu; G Serrero
Journal:  Proc Natl Acad Sci U S A       Date:  2001-01-02       Impact factor: 11.205

9.  Mechanisms of nordihydroguaiaretic acid-induced growth inhibition and apoptosis in human cancer cells.

Authors:  T Seufferlein; M J Seckl; E Schwarz; M Beil; G v Wichert; H Baust; H Lührs; R M Schmid; G Adler
Journal:  Br J Cancer       Date:  2002-04-08       Impact factor: 7.640

10.  βKlotho suppresses tumor growth in hepatocellular carcinoma by regulating Akt/GSK-3β/cyclin D1 signaling pathway.

Authors:  Xiaoming Ye; Yu Guo; Qi Zhang; Wenjie Chen; Xuefeng Hua; Wei Liu; Yang Yang; Guihua Chen
Journal:  PLoS One       Date:  2013-01-30       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.